QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

PHAR

QT48Pharming Group N.V.
NASDAQ·Healthcare·Biotechnology·NL
Latest market price
12.87
+0.22+1.74%
OverviewShort InterestFilings
PHARQT48Pharming Group N.V.·NASDAQ
OverviewShort InterestFilings
12.87+1.74%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E76.95EPS (ttm)
0.18
Insider Own-
Shs Outstand-
Perf Week-0.08%
Market Cap911.95MForward P/E65.92EPS next Y0.20Insider Trans-Shs Float-Perf Month2.14%
Enterprise Value974.98MPEG0.00EPS next Q0.06Inst Own-Short Float-Perf Quarter-16.81%
Income11.86MP/S2.47EPS this Y-4.03%Inst Trans-Short Ratio-Perf Half Y-22.42%
Sales369.26MP/B3.57EPS next Y13.02%ROA2.55%Short Interest-Perf YTD-27.16%
Book/sh-P/C18.22EPS next 5Y62.35%ROE4.75%52W High21.34 -39.69%Perf Year15.53%
Cash/sh-P/FCF17.56EPS past 3/5Y-ROIC3.76%52W Low9.54 34.91%Perf 3Y-
Dividend Est.-EV/EBITDA28.89Sales past 3/5Y22.32% 12.20%Gross Margin88.12%Volatility2.40% 3.57%Perf 5Y-
Dividend TTM-EV/Sales2.64EPS Y/Y TTM188.89%Oper. Margin6.36%ATR (14)0.55Perf 10Y-
Dividend Ex-Date-Quick Ratio2.06Sales Y/Y TTM19.48%Profit Margin3.37%RSI (14)46.13Recom2.00
Dividend Gr. 3/5Y-Current Ratio2.63EPS Q/Q68.18%SMA200.57%Beta1.31Target Price38.00
Payout0.00%Debt/Eq0.43Sales Q/Q-8.86%SMA50-10.87%Rel Volume0.28Prev Close12.65
Employees404LT Debt/Eq0.39EarningsJul 30SMA200-17.93%Avg Volume11.48KPrice12.87
IPO DateDec 23, 2020Option/ShortYes / YesEPS/Sales Surpr.-240.00% -21.74%Net Debt/EBITDA1.87Volume3,253Change1.74%
Analyst Ratings
DateActionAnalystRatingTarget
May-08-26ReiteratedOppenheimerOutperform$41 → $40
Apr-10-26InitiatedCanaccord on growth potentialBuy$37
Mar-12-26ReiteratedH.C. Wainwright$37
Nov-07-25ReiteratedOppenheimerOutperform$41 → $42
Dec-09-24ReiteratedJefferies$14
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue368377308
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A474637
Gross Profit322332271
Selling, General and Administrative Excl. Other237117103
Research and Development1059886
Other Operating Expense-449591
Operating Income2421-9
Interest Expense13219
Unusual Expense
———
Non-Operating Income (Expense)-8-3-9
Net Income Before Taxes2013-9
Income Taxes8103
Consolidated Net Income133-12
Net Income From Continuing Operations133-12
Net Income133-12
EPS (Recurring)0.190.04-0.18
EPS (Basic, Before Extraordinaries)0.190.04-0.18
EPS (Diluted)0.180.04-0.18
EBITDA393217
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio71.50441.75—
Price To Sales Ratio2.453.33—
Gross Margin87.5088.0687.99
Operating Margin6.525.57-2.92
Net Margin3.530.80-3.90
Shares Outstanding707169
Market Capitalization9011,255—
Operating Lease Expense
———
Insider Trading Volume
$14.01$11.53$9.05$6.58$4.10● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR